Prevailing plasmodium falciparum dihydrofolate reductase 108-asparagine in hodeidah, yemen: A questionable sulfadoxine-pyrimethamine partner within the artemisinin-based combination therapy

Acta Tropica

Volumn 132, Issue 1, 2014, Pages 39-44

  Abdul Ghani, Rashad ^a,b   Farag, Hoda F ^a   Allam, Amal F ^a   Shawky, Sherine M ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b SANA A UNIVERSITY   (Yemen)

Author keywords

Antimalarial drug resistance; Dihydrofolate reductase; Hodeidah; Sulfadoxine pyrimethamine

Indexed keywords

ARTEMISININ; ASPARAGINE; DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE PLUS SULFADOXINE;

ALLELE; ANTIBIOTIC RESISTANCE; ANTIMALARIAL AGENT; ENZYME; MALARIA; MUTATION; PARASITE; PARASITOLOGY; POLYMERASE CHAIN REACTION; POLYMORPHISM;

ARTICLE; BLOOD SAMPLING; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA EXTRACTION; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE AMPLIFICATION; HUMAN; MALARIA FALCIPARUM; MALE; MORBIDITY; MORTALITY; PLASMODIUM FALCIPARUM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; YEMEN;

ANTIMALARIAL DRUG RESISTANCE; DIHYDROFOLATE REDUCTASE; HODEIDAH; SULFADOXINE-PYRIMETHAMINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; ASPARAGINE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; YEMEN; YOUNG ADULT;

EID: 84892969337     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.12.022     Document Type: Article

References (66)

1. Abdul-Ghani R., Farag H.F., Allam A.F. Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context. Acta Tropica 2013, 125:163-190.
2. Abdul-Ghani R., Farag H.F., Allam A.F., Shawky S.M. Mutant Plasmodium falciparum chloroquine resistance transporter in Hodeidah, Yemen: association with parasitologic indices and treatment-seeking behaviors. Acta Tropica 2013, 128:473-478.
3. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., White N. Artesunate combinations for treatment of malaria: meta-analysis. The Lancet 2004, 363:9-17.
4. A-Elbasit I.E., Alifrangis M., Khalil I.F., Bygbjerg Ib.C., Masuadi E.M., Elbashir M.I., Giha H.A. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics. Malaria Journal 2007, 6:108.
5. Al-Farsi H.M., Al-Hashami Z.S., Bin Dajem S.M., Al-Sheikh A.A., Al-Qahtani A., Beja-Pereira A., Idris M.A., Babiker H.A. Source of drug resistant Plasmodium falciparum in a potential malaria elimination site in Saudi Arabia. Infection, Genetics & Evolution 2012, 12:1253-1259.
6. Al-Hamidhi S., Mahdy M.A., Al-Hashami Z., Al-Farsi H., Al-Mekhlafi A.M., Idris M.A., Beja-Pereira A., Babiker H.A. Genetic diversity of Plasmodium falciparum and distribution of drug resistance haplotypes in Yemen. Malaria Journal 2013, 12:244.
7. Al-Kabsi A.M., Al-Shamahy H.A., Al-Harazy A.H., Harmal N.S. The therapeutic efficacy of sulfadoxine/pyrimethamine against Plasmodium falciparum in Yemen. Medical Principles and Practice 2009, 18:62-66.
8. Alkadi H.O., Al-Maktari M.T., Nooman M.A. Chloroquine-resistant Plasmodium falciparum local strain in Taiz Governorate, Republic of Yemen. Chemotherapy 2006, 52:166-170.
9. Alker A.P., Lim P., Sem R., Shah N.K., Yi P., Bouth D.M., Tsuyuoka R., Maguire J.D., Fandeur T., Ariey F., Wongsrichanalai C., Meshnick S.R. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. American Journal of Tropical Medicine and Hygiene 2007, 76:641-647.
10. Al-Maktari M.T., Bassiouny H.K. Malaria status in Al-Hodeidah Governorate, Republic of Yemen. Part II: human factors causing the persistence of chloroquine resistant P. falciparum local strain. Journal of the Egyptian Society of Parasitology 2003, 33:829-839.
11. Al-Maktari M.T., Bassiouny H.K., Al-Hamd Z.S., Assabri A.M., El-Massry A.G., Shatat H.Z. Malaria status in Al-Hodeidah Governorate, Yemen: malariometric parasitic survey & chloroquine resistance of P. falciparum local strain. Journal of the Egyptian Society of Parasitology 2003, 33:361-372.
12. Al-Mekhlafi A.M., Fong M.Y., Azazy A.A., Mahdy M.A. Study on the prevalence of malaria among patients with fever in Hodiedah Province, Yemen. 45th Annual Scientific Seminar of the Malaysian Society of Parasitology and Tropical Medicine 2009, 55.
13. Al-Mekhlafi A.M., Mahdy M.A., Al-Mekhlafi H.M., Azazy A.A., Fong M.Y. High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy. Parasites & Vectors 2011, 4:94.
14. Al-Shamahy H., Al-Harazy A.H., Harmal N.S., Al-Kabsi A.M. The prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen. Annals of Saudi Medicine 2007, 27:432-436.
15. Ariey F., Witkowski B., Amaratunga C., Beghain J., Langlois A.C., Khim N., Kim S., Duru V., Bouchier C., Ma L., Lim P., Leang R., Duong S., Sreng S., Suon S., Chuor C.M., Bout D.M., Ménard S., Rogers W.O., Genton B., Fandeur T., Miotto O., Ringwald P., Le Bras J., Berry A., Barale J.C., Fairhurst R.M., Benoit-Vical F., Mercereau-Puijalon O., Ménard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2013, 505:50-55.
16. Artzy-Randrup Y., Alonso D., Pascual M. Transmission intensity and drug resistance in malaria population dynamics: implications for climate change. PLoS ONE 2010, 5:e13588.
17. Awab G.R., Pukrittayakamee S., Jamornthanyawat N., Yamin F., Dondorp A.M., Day N.P., White N.J., Woodrow C.J., Imwong M. Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Malaria Journal 2013, 12:96.
18. Barnes K.I., Little F., Mabuza A., Mngomezulu N., Govere J., Durrheim D., Roper C., Watkins B., White N.J. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. Journal of Infectious Diseases 2008, 197:1605-1613.
19. Bin Dajem S.M., Al-Farsi H.M., Al-Hashami Z.S., Al-Sheikh A.A., Al-Qahtani A., Babiker H.A. Distribution of drug resistance genotypes in Plasmodium falciparum in an area of limited parasite diversity in Saudi Arabia. American Journal of Tropical Medicine and Hygiene 2012, 86:782-788.
20. Bousema T., Roeffen W., Meijerink H., Mwerinde H., Mwakalinga S., van Gemert G.-J., van de Vegte-Bolmer M., Mosha F., Targett G., Riley E.M., Sauerwein R., Drakeley C. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS ONE 2010, 5:e14114.
21. Bouyou-Akotet M.K., Mawili-Mboumba D.P., Tchantchou Tde D., Kombila M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. Journal of Antimicrobial Chemotherapy 2010, 65:438-441.
22. Cheesbrough M. District Laboratory Practice in Tropical Countries: Part 1 2005, Cambridge University Press, London. 2nd ed.
23. Djimdé A.A., Doumbo O.K., Traore O., Guindo A.B., Kayentao K., Diourte Y., Niare-Doumbo S. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 2003, 69:558-563.
24. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., Ariey F., Hanpithakpong W., Lee S.J., Ringwald P., Silamut K., Imwong M., Chotivanich K., Lim P., Herdman T., An S.S., Yeung S., Singhasivanon P., Day N.P., Lindegardh N., Socheat D., White N.J. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine 2009, 361:455-467.
25. Faye B., Ndiaye M., Ndiaye J.L., Annie A., Tine R.C., Lo A.C., Sow D., De Sousa A., Gaye O. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitology Research 2011, 109:133-138.
26. Galindo J.A., Cristiano F.A., Knudson A., Nicholls R.S., Guerra A.P. Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia. Biomedica 2010, 30:56-64.
27. Greenwood B.M., Mutabingwa T. Malaria in 2002. Nature 2002, 415:670-672.
28. Heidari A., Dittrich S., Jelinek T., Kheirandish A., Banihashemi K., Keshavarz H. Genotypes and in vivo resistance of Plasmodium falciparum isolates in an endemic region of Iran. Parasitology Research 2007, 100:589-592.
29. Iyer J.K., Milhous W.K., Cortese J.F., Kublin J.G., Plowe C.V. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. The Lancet 2001, 358:1066-1067.
30. Jambou R., Legrand E., Niang M., Khim N., Lim P., Volney B., Ekala M.T., Bouchier C., Esterre P., Fandeur T., Mercereau-Puijalon O. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. The Lancet 2005, 366:1960-1963.
31. Jelinek T., Kilian A.H., Curtis J., Duraisingh M.T., Kabagambe G., von Sonnenburg F., Warhurst D.C. Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. American Journal of Tropical Medicine and Hygiene 1999, 61:125-130.
32. Khalil I.F., Ronn A.M., Alifrangis M., Gabar H.A., Jelinek T., Satti G.M., Bygbjerg I.C. Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes. American Journal of Tropical Medicine and Hygiene 2005, 73:174-177.
33. Kofoed P.E., Alfrangis M., Poulsen A., Rodrigues A., Gjedde S.B., Ronn A., Rombo L. Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau. Tropical Medicine & International Health 2004, 9:171-177.
34. Laxminarayan R., Bhutta Z.A., Duse A., Jenkins P., O'Brien T., Okeke I.N., Pablo-Mendez A., Klugman K.P. Drug resistance. Disease Control Priorities in Developing Countries 2006, 1031-1052. The World Bank, Washington, DC. D.T. Jamison, J.G. Breman, A.R. Measham, G. Alleyne, M. Claeson, D.B. Evans, P. Jha, A. Mills, P. Musgrove (Eds.).
35. Lozovsky E.R., Chookajorn T., Brown K.M., Imwong M., Shaw P.J., Kamchonwongpaisan S., Neafsey D.E., Weinreich D.M., Hartl D.L. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12025-12030.
36. Marks F., Evans J., Meyer C.G., Browne E.N., Flessner C., von Kalckreuth V., Eggelte T.A., Horstmann R.D., May J. High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrobial Agents and Chemotherapy 2005, 49:1101-1105.
37. Menegon M., Talha A.A., Severini C., Elbushra S.M., Mohamedani A.A., Malik E.M., Mohamed T.A., Wernsdorfer W.H., Majori G., Nour B.Y. Frequency distribution of antimalarial drug resistance alleles among Plasmodium falciparum isolates from Gezira State, central Sudan, and Gedarif State, eastern Sudan. American Journal of Tropical Medicine and Hygiene 2010, 83:250-257.
38. Mens P., Sawa P., van Amsterdam S., Versteeg I., Omar S., Schallig H., Kager P. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malaria Journal 2008, 7:237.
39. Mharakurwa S., Kumwenda T., Mkulama M.A., Musapa M., Chishimba S., Shiff C.J., Sullivan D.J., Thuma P.E., Liu K., Agre P. Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:18796-18801.
40. Mockenhaupt F.P., Teun Bousema J., Eggelte T.A., Schreiber J., Ehrhardt S., Wassilew N., Otchwemah R.N., Sauerwein R.W., Bienzle U. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Tropical Medicine & International Health 2005, 10:901-908.
41. Mubjer R., Adeel A., Chance M., Hassan A. Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications. Malaria Journal 2011, 10:245.
42. Ndounga M., Tahar R., Basco L.K., Casimiro P.N., Malonga D.A., Ntoumi F. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo. Tropical Medicine & International Health 2007, 12:1164-1171.
43. Nkhoma S., Molyneux M., Ward S. Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Tropica 2007, 102:138-142.
44. National Malaria Control Program Yemen's National Malaria Control and Elimination Strategic Plan (2011-2015) 2010, NMCP/Ministry of Public Health and Population, Sana'a.
45. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. Artemisinin resistance in Cambodia 1 (ARC1) study consortium, evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine 2008, 359:2619-2620.
46. Ogouyemi-Hounto A., Ndam N.T., Kinde Gazard D., d'Almeida S., Koussihoude L., Ollo E., Azagnandji C., Bello M., Chippaux J.P., Massougbodji A. Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy. Malaria Journal 2013, 12:147.
47. Ojurongbe O., Tijani B.D., Fawole A.A., Adeyeba O.A., Kun J.F. Prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum isolate from pregnant women in Nigeria. Infectious Disease Reports 2011, 3:e16.
48. Omar S.A., Adagu I.S., Warhurst D.C. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:315-319.
49. Phyo A.P., Nkhoma S., Stepniewska K., Ashley E.A., Nair S., McGready R., ler Moo C., Al-Saai S., Dondorp A.M., Lwin K.M., Singhasivanon P., Day N.P., White N.J., Anderson T.J., Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. The Lancet 2012, 379:1960-1966.
50. Plowe C.V. PCR-Allele-Specific Restriction Analysis (ASRA): Protocols for Plasmodium falciparum Drug Resistance Mutation Analyses 2002, University of Maryland.
51. Plowe C.V. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Current Topics in Microbiology and Immunology 2005, 295:55-79.
52. Raman J., Little F., Roper C., Kleinschmidt I., Cassam Y., Maharaj R., Barnes K.I. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. American Journal of Tropical Medicine and Hygiene 2010, 82:788-794.
53. Schonfeld M., Barreto Miranda I., Schunk M., Maduhu I., Maboko L., Hoelscher M., Berens-Riha N., Kitua A., Loscher T. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malaria Journal 2007, 6:2.
54. Sendagire H., Kaddumukasa M., Ndagire D., Aguttu C., Nassejje M., Pettersson M., Swedberg G., Kironde F. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Tropica 2005, 95:172-182.
55. Shah M., Kariuki S., Vanden Eng J., Blackstock A.J., Garner K., Gatei W., Gimnig J.E., Lindblade K., Terlouw D., ter Kuile F., Hawley W.A., Phillips-Howard P., Nahlen B., Walker E., Hamel M.J., Slutsker L., Shi Y.P. Effect of transmission reduction by insecticide-treated bednets (ITNs) on antimalarial drug resistance in western Kenya. PLoS ONE 2011, 6:e26746.
56. Sibley C.H., Hyde J.E., Sims P.F.G., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology 2001, 17:582-588.
57. Sirawaraporn W., Yongkiettrakul S., Sirawaraporn R., Yuthavong Y., Santi D.V. Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Experimental Parasitology 1997, 87:245-252.
58. Sridaran S., McClintock S., Syphard L., Herman K., Barnwell J., Udhayakumar V. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malaria Journal 2010, 9:247.
59. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., Rosenthal P.J. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Tropical Medicine & International Health 2004, 9:624-629.
60. Tarimo D.S. Emergence of mutations sssociated with resistance to sulfadoxine-pyrimethamine (SP) after single therapeutic dose: implications on the useful therapeutic life of SP in malaria holoendemic areas. East African Journal of Public Health 2005, 2:28-31.
61. Tsumori Y., Ndounga M., Sunahara T., Hayashida N., Inoue M., Nakazawa S., Casimiro P., Isozumi R., Uemura H., Tanabe K., Kaneko O., Culleton R. Plasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of Congo. PLoS ONE 2011, 6:e23430.
62. Watkins W.M., Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993, 87:75-78.
63. White N.J., Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proceedings of the Royal Society B: Biological Sciences 2003, 270:545-554.
64. WHO World Malaria Report 2010 2010, World Health Organization, Geneva.
65. WHO World Malaria Report 2011 2011, World Health Organization, Geneva.
66. Zakeri S., Farahani M.S., Afsharpad M., Salehi M., Raeisi A., Djadid N.D. High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine. International Journal of Infectious Diseases 2010, 14(Suppl. 3):e123-e128.